Ma Mengmeng, Wang Jing, Jiang Hao, Chen Qiushui, Xiao Yi, Yang Huanghao, Lin Li
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
MOE Key Laboratory for Analytical Science of Food Safety and Biology and State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350108, China.
Acta Biomater. 2023 Jan 1;155:635-643. doi: 10.1016/j.actbio.2022.10.049. Epub 2022 Nov 1.
Non-invasive phototherapy has been emerging as an ambitious tactic for suppression of amyloid-β (Aβ) self-assembly against Alzheimer's disease (AD). However, it remains a daunting challenge to develop efficient photosensitizers for Aβ oxygenation that are activatable in a deep brain tissue through the scalp and skull, while reducing side effects on normal tissues. Here, we report an Aβ targeted, low-dose X-ray-excitable long-afterglow scintillator (ScNPs@RB/Ab) for efficient deep-brain phototherapy. We demonstrate that the as-synthesized ScNPs@RB/Ab is capable of converting X-rays into visible light to activate the photosensitizers of rose bengal (RB) for Aβ oxygenation through the scalp and skull. We show that the ScNPs@RB/Ab persistently emitting visible luminescence can substantially minimize the risk of excessive X-ray exposure dosage. Importantly, peptide KLVFFAED-functionalized ScNPs@RB/Ab shows a blood-brain barrier permeability. In vivo experimental results validated that ScNPs@RB/Ab alleviated Aβ burden and slowed cognitive decline in triple-transgenic AD model mice at extremely low X-ray doses without side effects. Our study paves a new pathway to develop high-efficiency transcranial AD phototherapy. STATEMENT OF SIGNIFICANCE: Non-invasive phototherapy has been emerging as an ambitious tactic for suppression of amyloid-β (Aβ) self-assembly against Alzheimer's disease (AD). However, it remains a daunting challenge to develop efficient photosensitizers for Aβ oxygenation that are activatable in a deep brain tissue through the scalp and skull, while reducing side effects on normal tissues. Herein, we report an Aβ targeted, low-dose X-ray-excitable long-afterglow scintillators (ScNPs@RB/Ab) for efficient deep-brain phototherapy. In vivo experimental results validated that ScNPs@RB/Ab alleviated Aβ burden and slowed cognitive decline in triple-transgenic AD model mice at extremely low X-ray doses without side effects.
非侵入性光疗已成为一种抑制淀粉样β蛋白(Aβ)自组装以对抗阿尔茨海默病(AD)的宏伟策略。然而,开发能够通过头皮和颅骨在深部脑组织中被激活、同时减少对正常组织副作用的高效用于Aβ氧化的光敏剂,仍然是一项艰巨的挑战。在此,我们报道了一种用于高效深部脑光疗的Aβ靶向、低剂量X射线可激发的长余辉闪烁体(ScNPs@RB/Ab)。我们证明,合成的ScNPs@RB/Ab能够将X射线转化为可见光,以激活孟加拉玫瑰红(RB)的光敏剂,从而通过头皮和颅骨实现Aβ氧化。我们表明,持续发射可见光的ScNPs@RB/Ab可大幅降低X射线过量暴露剂量的风险。重要的是,经肽KLVFFAED功能化的ScNPs@RB/Ab显示出了血脑屏障通透性。体内实验结果证实,ScNPs@RB/Ab在极低的X射线剂量下减轻了三转基因AD模型小鼠的Aβ负担,并减缓了认知衰退,且无副作用。我们的研究为开发高效的经颅AD光疗开辟了一条新途径。重要性声明:非侵入性光疗已成为一种抑制淀粉样β蛋白(Aβ)自组装以对抗阿尔茨海默病(AD)的宏伟策略。然而,开发能够通过头皮和颅骨在深部脑组织中被激活、同时减少对正常组织副作用的高效用于Aβ氧化的光敏剂,仍然是一项艰巨的挑战。在此,我们报道了一种用于高效深部脑光疗的Aβ靶向、低剂量X射线可激发的长余辉闪烁体(ScNPs@RB/Ab)。体内实验结果证实,ScNPs@RB/Ab在极低的X射线剂量下减轻了三转基因AD模型小鼠的Aβ负担,并减缓了认知衰退,且无副作用。